The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; none of the 25 sources its claims cite is checked for support yet.
Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Open accessAbstract
Temperature-sensitive (ts) mutations have been used as a genetic and molecular tool to study the functions of many gene products. Each ts mutant protein may contain a temperature-dependent intramolecular mechanism such as ts conformational change. To identify key ts structural elements controlling the protein function, we screened ts p53 mutants from a comprehensive mutation library consisting of 2,314 p53 missense mutations for their sequence-specific transactivity through p53-binding sequences in Saccharomyces cerevisiae. We isolated 142 ts p53 mutants, including 131 unreported ts mutants. These mutants clustered in beta-strands in the DNA-binding domain, particularly in one of the two beta-sheets of the protein, and 15 residues (Thr155, Arg158, Met160, Ala161, Val172, His214, Ser215, Pro223, Thr231, Thr253, Ile254, Thr256, Ser269, Glu271, and Glu285) were ts hot spots. Among the 142 mutants, 54 were examined further in human osteosarcoma Saos-2 cells, and it was confirmed that 89% of the mutants were also ts in mammalian cells. The ts mutants represented distinct ts transactivities for the p53 binding sequences and a distinct epitope expression pattern for conformation-specific anti-p53 antibodies. These results indicated that the intramolecular beta-sheet in the core DNA-binding domain of p53 was a key structural element controlling the protein function and provided a clue for finding a molecular mechanism that enables the rescue of the mutant p53 function.
Overview
CoChat Summary
TL;DR
Screening 2,314 p53 missense mutants in yeast identified 142 temperature-sensitive (ts) p53 mutants, including 131 previously unreported. The ts mutants clustered in β-strands of the DNA-binding domain, and most tested also showed ts transactivation in mammalian cells.
Key findings
- From 2,314 p53 missense mutations, 142 ts mutants were selected (6.1%); 131 were previously unreported. Of these, 131 (92%) mapped within the core DNA-binding domain (residues 97–286), and 70 (53.4%) mapped on β-strands; 15 residues were ts hot spots: Thr155, Arg158, Met160, Ala161, Val172, His214, Ser215, Pro223, Thr231, Thr253, Ile254, Thr256, Ser269, Glu271, and Glu285.
- In p53-deficient Saos-2 cells, 54 mutants were tested and 48 (89%) were ts in at least one of six promoters; 16 were ts in all six promoters, while 32 were ts in a limited number.
- Among six mutants examined with conformation-sensitive antibodies, P219S and T253I showed an obvious ts increase in the PAb1620/PAb240 ratio; R175H and R273H were not ts by this assay.
- In the IARC database, 10.3% (110 of 1,066) of distinct single-nucleotide missense mutants and 10.4% (1,254 of 12,032) of total mutation reports were thought to be ts.
Methods
- A library of 2,314 p53 missense mutations was stably expressed in haploid or diploid *Saccharomyces cerevisiae* strains with p53-responsive fluorescent reporters, including p21WAF1, MDM2, BAX, 14-3-3, p53AIP1, GADD45, Noxa, and p53R2; fluorescence was measured at 30 and 37 °C. Ts mutants met the criteria M30/W30 ≥ 0.7, M37/W37 ≤ 0.5, and M30/M37 ≥ 2.
- Mammalian validation used p53-deficient human osteosarcoma Saos-2 cells: 54 mutants were tested by luciferase assay with six promoters at 32 and 37 °C, with ts defined by t test p < 0.001; immunoprecipitation used PAb1620 and PAb240, and mapping used the 1TUP structure visualized with Cn3D.
Limitations
- The paper states that ts criteria were strict and differed between yeast and mammalian systems, so some ts mutants may be defined in one system but not the other; previously reported ts mutants may have been missed because of different assays, weak ts phenotypes, or mechanisms absent in yeast, such as V143A requiring human ASPP2.
- Evident in the text: only 54 of 142 yeast-isolated ts mutants were tested in mammalian cells, and only six were examined by conformation-sensitive antibodies, so mammalian ts frequency and epitope findings rest on subsets.
- The paper notes that ts transactivity spectra differed in part between human and yeast cells and speculates this may be due to different p53 binding elements, temperatures, and post-translational or protein-interaction contexts.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
0 Valid · 0 Not valid · 22 Not checked · 60 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and a distinct epitope expression pattern for conformation-specific anti-p53 antibodies.”
§ Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the cluster analysis found the typical ts mutants that represent temperature sensitivity for most p53 binding sites, there are mutants that show temperature sensitivity on limited types of p53 binding sites and, therefore, are not clustered.”
§ Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* > Isolation of ts p53
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among these, 70 mutants (53.4%) were mapped on the -strands.”
§ Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* > Mapping of ts p53 Mutants on p53
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Obviously, there were significant numbers of p53 mutant clones that represented higher transactivity at 30 °C than at 37 °C, showing ts mutants for the transactivation function (circled spots in Fig. 2).”
§ Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* > Isolation of ts p53
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Notably, there is one temperature-dependent sub-cluster within the latter cluster (Fig. 1B).The cluster consists of 64 p53 mutants, and the transactivities of the mutants are inactive on almost all p53 binding sites at 37 °C but active on some p53 binding sites at 30 °C”
§ Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* > Clustering of 2,314
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
39 more claims
Create a free account to see all 82 claims and every source verdict.
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
- Probably not a substantial claim. 16
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Most were mapped in the core DNA-binding domain (131, 91.5%), and a few were in the NH 2 -terminal (4, 3.5%) or COOHterminal (7, 4.9%) domains.”
§ Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* > Additional information
Reported 3.5 · recomputed 2.816901
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* > Mapping of ts p53 Mutants on p53
“Among these, 70 mutants (53.4%) were mapped on the -strands.”
§ Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* > Additional information
“Within the DNA-biding domain, 50% (71 of 142) of the ts mutants were mapped on -strands (S1-S10).”
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Prediction of the Secondary Structure of Proteins from their Amino Acid Sequence
Chou, P. Y., & Fasman, G. D. (1979) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470122921.ch2 · Cited by 2,915
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Research works printed but not linked: 5
- Soussi, 1990, Oncogene., 5, 945
- Shimada, 1999, Cancer Res., 59, 2781
- Chou, 1978, Adv. Enzymol. Relat. Areas Mol. Biol., 47, 45
- Rolley, 1995, Oncogene., 11, 763
- Siddik, 1998, Cancer Res., 58, 698
Cited by
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors
Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D., Kutok, J. L., Fletcher, C. D. M., Morris, J. P., Liu, T. X., Schulte-Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 597
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436
Structure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 353
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Le Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0551 · Cited by 273
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Solution structure of p53 core domain: Structural basis for its instability
Cañadillas, J. M. P., Tidow, H., Freund, S. M. V., Rutherford, T. J., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510941103 · Cited by 174
Dearth, L. R., Qian, H., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 120
Soussi, T., Kato, S., Lévy, P., & Ishioka, C. (2004) · Human Mutation · doi:10.1002/humu.20114 · Cited by 156
Self-citationStructural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants
(2007) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)97001-8 · Cited by 106
TP53 Germline Mutations in Adult Patients with Adrenocortical Carcinoma
Herrmann, L. J. M., Heinze, B., Fassnacht, M., Willenberg, H. S., Quinkler, M., Reisch, N., Zink, M., Allolio, B., & Hahner, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1982 · Cited by 109
Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Räty, J. K., Pikkarainen, J. T., Wirth, T. C., & Ylä‐Herttuala, S. (2008) · Current Molecular Pharmacology · doi:10.2174/1874467210801010013 · Cited by 118
Kakudo, Y., Shibata, H., Otsuka, K., Kato, S., & Ishioka, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2935 · Cited by 101
Self-citationSmall molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2011) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 96
Mutant TP53 Posttranslational Modifications: Challenges and Opportunities
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W. (2014) · Human Mutation · doi:10.1002/humu.22506 · Cited by 69
Jordan, J. J., Inga, A., Conway, K., Edmiston, S. N., Carey, L., Wu, L., & Resnick, M. A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0442 · Cited by 81
Whole-genome cartography of p53 response elements ranked on transactivation potential
Tebaldi, T., Zaccara, S., Alessandrini, F., Bisio, A., Ciribilli, Y., & Inga, A. (2015) · BMC Genomics · doi:10.1186/s12864-015-1643-9 · Cited by 72
Müller, P., Češková, P., & Vojtesek, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412767200 · Cited by 75
Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer
Villiard, É., Brinkmann, H., Moiseeva, O. V., Mallette, F. A., Ferbeyre, G., & Roy, S. (2007) · BMC Evolutionary Biology · doi:10.1186/1471-2148-7-180 · Cited by 67
Song, H., Wu, J., Tang, Y., Dai, Y., Xiang, X., Li, Y., Wu, L., Wu, J., Liang, Y., Xing, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9155 · Cited by 62
Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China
Xia, Y., Li, X., & Sun, W. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200731003206 · Cited by 53
Tagawa, M. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s3535 · Cited by 49
Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
Voropaeva, E. N., Pospelova, T. I., Voevoda, M. I., Maksimov, V. N., Orlov, Y. L., & Seregina, O. B. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0484-9 · Cited by 45
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Szeto, C. Y. Y., Lin, C. H., Choi, S. C., Yip, T. T. C., Ngan, R. K., Tsao, G. S., & Lung, M. L. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.01.004 · Cited by 47
Barakat, K., Issack, B. B., Stepanova, M., & Tuszyński, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027651 · Cited by 44
TP53 Mutants in the Tower of Babel of Cancer Progression
Bisio, A., Ciribilli, Y., Fronza, G., Inga, A., & Monti, P. (2014) · Human Mutation · doi:10.1002/humu.22514 · Cited by 49
Development of an adenoviral vector with robust expression driven by p53
Bajgelman, M. C., & Strauss, B. E. (2008) · Virology · doi:10.1016/j.virol.2007.11.015 · Cited by 43
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30
Ginsburg, O., Akbari, M. R., Aziz, Z., Young, R., Lynch, H. T., Ghadirian, P., Robidoux, A., Hernández, J. E. L., Vásquez, G., Gomes, M. C. B., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9287-z · Cited by 45
The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53
Bajgelman, M. C., & Strauss, B. E. (2006) · The Prostate · doi:10.1002/pros.20462 · Cited by 39
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110622 · Cited by 37
Monteith, J., Mellert, H. S., Sammons, M. A., Kuswanto, L. A., Sykes, S. M., Resnick‐Silverman, L., Manfredi, J. J., Berger, S. L., & McMahon, S. B. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.05.007 · Cited by 36
Mueller, S., Grote, I., Bartels, S., Kandt, L. D., Christgen, H., Lehmann, U., Gluz, O., Graeser, M., Kates, R., Harbeck, N., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100100 · Cited by 33
Christgen, M., Noskowicz, M., Heil, C., Schipper, E., Christgen, H., Geffers, R., Kreipe, H. H., & Lehmann, U. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.126 · Cited by 33
Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson
Menéndez, D., Inga, A., Jordan, J. J., & Resnick, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210277 · Cited by 40
Pahuja, K. B., Dewan, P. C., Chakrabarti, P., Goswami, D., Barua, B., Baliga, C., & Varadarajan, R. (2008) · Biochemistry · doi:10.1021/bi8014345 · Cited by 32
Update on oncolytic viral therapy – targeting angiogenesis
Tysome, J. R., Lemoine, N. R., & Wang, Y. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s46974 · Cited by 32
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types
Sasaki, K., Takahashi, S. I., Ouchi, K., Otsuki, Y., Wakayama, S., & Ishioka, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-32092-8 · Cited by 31
Self-citationFunctional analysis of p53 tumor suppressor in yeast
Šmardová, J., Šmarda, J., & Koptíková, J. (2005) · Differentiation · doi:10.1111/j.1432-0436.2005.00028.x · Cited by 41
The screening of the second‐site suppressor mutations of the common p53 mutants
Otsuka, K., Kato, S., Kakudo, Y., Mashiko, S., Shibata, H., & Ishioka, C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22724 · Cited by 23
Self-citationBalourdas, D.-I., Markl, A. M., Krämer, A., Settanni, G., & Joerger, A. C. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06739-x · Cited by 24
rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy
Chen, G., Zheng, L.-H., Liu, S.-Y., & He, X.-H. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i38.4289 · Cited by 25
Grochová, D., Vaňková, J., Damborský, J., Ravčuková, B., Šmarda, J., Vojtěšek, B., & Šmardová, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210748 · Cited by 29
Huang, M., Wu, Y., Wei, X., Cheng, L., Fu, L., Yan, H., Wei, W., Li, B., Ru, H., Mo, X., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07541-z · Cited by 24
In the Quest for Stable Rescuing Mutants of p53: Computational Mutagenesis of Flexible Loop L1
Pan, Y., Ma, B., Venkataraghavan, R. B., Levine, A. J., & Nussinov, R. (2005) · Biochemistry · doi:10.1021/bi047845y · Cited by 24
Wu, T., Chen, W., Zhong, Y., Hou, X., Fang, S., Liu, C., Wang, G., Yu, T., Huang, Y., Ouyang, X., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0553 · Cited by 24
Comparison of the Human and Worm p53 Structures Suggests a Way for Enhancing Stability
Pan, Y., Ma, B., Levine, A. J., & Nussinov, R. (2006) · Biochemistry · doi:10.1021/bi052242n · Cited by 22
Hypothermia Effectively Treats Tumors with Temperature-Sensitive p53 Mutations
Lu, J., Chen, L., Song, Z., Das, M., & Chen, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0033 · Cited by 21
Targeting p53 by PTD-mediated transduction
Wang, W., & El‐Deiry, W. S. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.07.002 · Cited by 19
Timofeev, O. N., & Stiewe, T. (2021) · Cancers · doi:10.3390/cancers13102422 · Cited by 19
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Monti, P., Bosco, B., Gomes, S., Saraiva, L., Fronza, G., & Inga, A. (2019) · Journal of Visualized Experiments · doi:10.3791/59071 · Cited by 18
p53, p63 and p73 in the wonderland ofS. cerevisiae
Billant, O., Blondel, M., & Voisset, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18506 · Cited by 19
Mutant p53: evolving perspectives
Efe, G., Cunningham, K. M., Rustgi, A. K., Prives, C. L., Manfredi, J. J., & Rivera, F. J. S. (2025) · Genes & Development · doi:10.1101/gad.353408.125 · Cited by 18
Establishment and characterization of a new human gallbladder carcinoma cell line.
Sekine, S., Shimada, Y., Nagata, T., Moriyama, M., Omura, T., Yoshioka, I., Hori, R., Koushi, M., Sawada, S., Okumura, T., et al. (2012) · PubMed · Cited by 17
Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer
Betancor-Fernández, I., Timson, D. J., SALIDO, E. C., & Pey, A. L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_55 · Cited by 17
Structural assessment of single amino acid mutations: application to TP53 function
Yip, Y. L., Zoete, V., Scheib, H., & Michielin, O. A. (2006) · Human Mutation · doi:10.1002/humu.20379 · Cited by 16
Neighborhood Properties Are Important Determinants of Temperature Sensitive Mutations
Lockwood, S., Krishnamoorthy, B., & Ye, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028507 · Cited by 15
Gene therapy and nasopharyngeal carcinoma
Hughes, J., Alusi, G., & Wang, Y. (2012) · Rhinology Journal · doi:10.4193/rhino11.239 · Cited by 14
Analysis of p53 Gene Alterations in Cancer: A Critical View
Soussi, T. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_12 · Cited by 18
Zhao, H., Zhang, Q., Yang, Y., Lu, M.-Q., Li, H., 徐池, & Chen, G.-H. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i5.683 · Cited by 13
Human transcription factors in yeast: the fruitful examples of P53 and NF-кB
Sharma, V., Monti, P., Fronza, G., & Inga, A. (2016) · FEMS Yeast Research · doi:10.1093/femsyr/fow083 · Cited by 11
Voropaeva, E. N., Pospelova, T. I., Voevoda, M. I., & Maksimov, V. N. (2017) · Molecular Biology · doi:10.1134/s0026893316060224 · Cited by 11
Jagošová, J., Pitrová, L., Slováčková, J., Ravčuková, B., Šmarda, J., & Šmardová, J. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1520 · Cited by 12
Not gene therapy, but genetic surgery—the right strategy to attack cancer
Sverdlov, E. D. (2009) · Molecular Genetics Microbiology and Virology · doi:10.3103/s089141680903001x · Cited by 9
Bhattacharjee, S., & Sengupta, J. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.08.037 · Cited by 8
Koulgi, S., Achalere, A., Sonavane, U., & Joshi, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143065 · Cited by 8
Koulgi, S., Achalere, A., Sonavane, U., & Joshi, R. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00380 · Cited by 7
High Frequency of Temperature-Sensitive Mutants of p53 in Glioblastoma
Šmardová, J., Lišková, K., Ravčuková, B., Kubiczková, L., Ševčíková, S., Michálek, J., Svitáková, M., Vybíhal, V., Křen, L., & Šmarda, J. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-012-9596-7 · Cited by 7
Farooqi, K. M., Ghazvini, M., Pride, L. D., Mazzella, L., White, D. E., Pramanik, A., Bargonetti, J., & Moore, C. W. (2020) · Biomolecules · doi:10.3390/biom10030417 · Cited by 8
Viral gene therapy for head and neck cancer
Hughes, J., Alusi, G., & Wang, Y. (2015) · The Journal of Laryngology & Otology · doi:10.1017/s0022215114003247 · Cited by 7
Mavridi, D., Funk, J. S., Balourdas, D.-I., Krämer, A., Tareque, R. K., Timofeev, O. N., Spencer, J., Stiewe, T., & Joerger, A. C. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08492-9 · Cited by 6
Imai, H., Kato, S., SAKAMOTO, Y., Kakudo, Y., Shimodaira, H., & Ishioka, C. (2013) · Oncology Reports · doi:10.3892/or.2013.2953 · Cited by 6
Self-citationValverde, G. L., García‐Martín, E., Povés, J. M. L., Polo, V., & Pablo, L. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156317 · Cited by 6
The Spectrum of Germline Nucleotide Variants in Gastric Cancer Patients in the Kyrgyz Republic
Bilyalov, A. I., Nikolaev, S., Михайловна, Д. А., Khatkov, I. E., Makhmudov, K., Isakova, J. T., Bakirov, N., Omurbaev, E., Osipova, A., Ramaldanov, R., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080403 · Cited by 5
Hypothermia Is a Potential New Therapy for a Subset of Tumors with Mutant p53
Hu, W., & Feng, Z. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1025 · Cited by 5
Synergistic rescue of temperature‐sensitive p53 mutants by hypothermia and arsenic trioxide
Lu, J., Chen, L., Fatima, Z., Huang, J. J., & Chen, J. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23804 · Cited by 3
Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells
Donninger, H., Binder, A. B., Böhm, L., & Parker, M. I. (2007) · Biological Chemistry · doi:10.1515/bc.2008.010 · Cited by 4
Choosing Targets for Gene Therapy
Karina, J., Ruben, R. J., James, R., & Carol, S. (2011) · InTech eBooks · doi:10.5772/22528 · Cited by 2
Characterization of p53 p.T253I as a pathogenic mutation underlying Li-Fraumeni Syndrome
Holcomb, N., Harrington, A., Pu, H., Halilovic, B., Shelman, N. R., Zhang, S., Sears, C., Armstrong, T., Shelton, B. J., Corum, L., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320036 · Cited by 1
Does fever drive the evolution of antiviral genes?
Langlois, R. A. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20251747 · Cited by 1
Kasahara, Y., Takahashi, M., Kawamura, Y., Aoki, Y., Niihori, T., Kawamura, M., Yamamoto, S., Shirota, H., Saijo, K., Imai, H., et al. (2026) · Familial Cancer · doi:10.1007/s10689-026-00529-4 · Cited by 1
Self-citationDARPins as pan-reactivators of temperature-sensitive p53 cancer mutants
Münick, P., Balourdas, D.-I., Funk, J. S., Yüksel, B., Mavridi, D., Heftel, J., Dreier, B., Schaefer, J. V., Schäfer, B., Knapp, S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2531747123 · Cited by 2
Molecular Biology of the Oral Cancer
Sasahira, T., & Kuniyasu, H. (2015) · Springer eBooks · doi:10.1007/978-4-431-54938-3_3 · Cited by 1
Valverde, G. L., García‐Martín, E., Povés, J. M. L., Polo, V., Fernández-Mateos, J., Pablo, L. E., & González‐Sarmiento, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171395 · Cited by 1
Chen, E. I.-T., Wu, J., Su, W.-H., Wang, T., & Au, L. (2009) · doi:10.6136/jms.2009.29(4).179
Brazilian Story of the R337H p53 Mutation
Šmardová, J., & Koptíková, J. (2014) · Klinicka onkologie · doi:10.14735/amko2014247 · Cited by 3
A Novel Intramolecular Interaction in P53
He, F. (2020) · Digital Commons - University of South Florida (University of South Florida)
Itoh, T. Q., Yildirim, E., Surabhi, S., Braun, R., & Allada, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.21.481387
Kakudo, Y., Shibata, H., Otsuka, K., Kato, S., & Ishioka, C. (2023) · doi:10.1158/0008-5472.22364477
Self-citationJordan, J. J., Inga, A., Conway, K., Edmiston, S. N., Carey, L., Wu, L., & Resnick, M. A. (2023) · doi:10.1158/1541-7786.c.6542128
Shaikh, D. H., Park, M. M., Chen, J., Huang, J. J., Friedman, M., Dam, A. N., Luthra, A., Cappelle, S., Peña, L., Permuth, J. B., et al. (2024) · Medicina · doi:10.3390/medicina60111901
Metadata
- Authors
- Shiraishi, K., Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., & Ishioka, C.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Ishioka, Chikashi
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-01
- Volume
- 279
- Issue
- 1
- Pages
- 348-355
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2119084812
- Cited by
- 96
- References
- 41
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 2 · 2017: 4 · 2016: 6 · 2015: 5 · 2014: 4 · 2013: 4 · 2012: 4
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6145 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, temperature-sensitive mutation, DNA-binding domain, beta-sheet, transcriptional activation, Saccharomyces cerevisiae, hot spots, epitope expression, anti-p53 antibodies, Saos-2 cells
- MeSH terms
- Amino Acid Sequence, Binding Sites, DNA, Molecular Sequence Data, Recombinant Proteins, Saccharomyces cerevisiae, Spectrometry, Fluorescence, Gene Library, Tumor Suppressor Protein p53, Mutagenesis, Site-Directed, Amino Acid Substitution, Mutation, Missense
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-15, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-15 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.